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Abstract
Background: Previous studies have shown that the presence of anemia is associated with increased short- and long-
term outcomes in patients with acute myocardial infarction (AMI). This study aims at examining the impact of
admission anemia on long-term, all-cause mortality following AMI in patients recruited from a population-based
registry. Contrary to most prior studies, we distinguished between patients with mild and moderate to severe anemia.
Methods: This prospective study was conducted in 2011 patients consecutively hospitalized for AMI that occurred
between January 2005 and December 2008. Patients who survived more than 28 days after AMI were followed up until
December 2011. Hemoglobin (Hb) concentration was measured at hospital admission and classified according to the
World Health Organization (WHO). Mild anemia was defined as Hb concentration of 11 to < 12 g/dL in women and 11
to < 13 g/dL in men; moderate to severe anemia as Hb concentration of < 11 g/dL. Adjusted Cox regression models
were calculated to compare survival in patients with and without anemia.
Results: Mild anemia and moderate to severe anemia was found in 183 (9.1%) and 100 (5%) patients, respectively.
All-cause mortality after a median follow-up time of 4.2 years was 11.9%. The Cox regression analysis showed
significantly increased mortality risks in both patients with mild (HR 1.74, 95% CI 1.23–2.45) and moderate to severe
anemia (HR 2.05, 95% CI 1.37–3.05) compared to patients without anemia.
Conclusion: This study shows that anemia adversely affects long-term survival following AMI. However, further studies
are needed to confirm that anemia can solely explain worse long-term outcomes after AMI.
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Background
Anemia found in patients with acute myocardial infarc-
tion (AMI) and measured at hospital admission has been
identified as an independent predictor of adverse out-
comes such as cardiac events, major bleeding as well as
short- and long-term mortality [1–5]. Defined according
to the World Health Organization (WHO), anemia is
present in women and men if hemoglobin (Hb) concen-
tration falls below 12 g/dL and 13 g/dL, respectively [6].
Compared with the prevalence in the general population
(3.8%) [7], anemia is more frequently encountered in pa-
tients hospitalized for cardiac events [8, 9]. Ranging
from 11% to 38% the presence of anemia varied widely
across prior studies in patients with AMI [10, 11].
The majority of previous studies in patients with AMI
focused on comparing those with and without anemia
* Correspondence: miriam.colombo@helmholtz-muenchen.de
1MONICA/KORA Myocardial Infarction Registry, Central Hospital of Augsburg,
Augsburg, Germany
2Institute of Epidemiology, Helmholtz Zentrum München, German Research
Center for Environmental Health (GmbH), Neuherberg, Germany
Full list of author information is available at the end of the article
© The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Colombo et al. BMC Cardiovascular Disorders  (2018) 18:50 
https://doi.org/10.1186/s12872-018-0785-5
neglecting severity of anemia. However, since it is a
common condition found in hospitalized patients, sever-
ity of anemia might be important to consider [11]. In
addition, results from long-term studies covering obser-
vation periods beyond 5 years are scarce. Therefore, the
aim of this study was to examine the association
between admission anemia and long-term, all-cause
mortality in patients with AMI recruited from the
MONICA/KORA myocardial infarction registry and to
incorporate severity of anemia into the analysis.
Methods
The data for this study were derived from the Myocardial
Infarction Registry that was established in Augsburg as
part of the WHO project MONICA (Monitoring Trends
and Determinants in Cardiovascular disease) in 1984. All
coronary deaths and cases of non-fatal AMI occurring
among the inhabitants of the city of Augsburg and the 2
adjacent counties (600,000 inhabitants) have been con-
tinuously registered since then. The population-based
registry was included into the KORA (Cooperative Health
Research in the Region of Augsburg) framework when the
MONICA project ended in 1995.
Patients aged between 25 and 74 years, who were admit-
ted to one out of 8 hospitals in the study area were in-
cluded. Written informed consent had to be obtained
before patients were included into the cohort. More detailed
information on case identification, diagnostic classification
of events and quality control of the data can be found in
previous publications [12, 13]. Trained study nurses inter-
viewed the participants during hospital stay using a stan-
dardized questionnaire. In order to confirm the information
provided by the patients and to collect additional informa-
tion, the patients’ medical chart was reviewed. Both
methods of data collection and questionnaires have been
approved by the ethics committee of the Bavarian Medical
Association (Bayerische Landesärztekammer) and the study
was performed in accordance with the Declaration of
Helsinki.
We conducted this prospective study in consecutive pa-
tients hospitalized for AMI between January 1, 2005 and
December 31, 2008. Patients were followed up for all-cause
mortality, the outcome of this study, until December 31,
2011. The vital status of study participants after hospital
discharge was determined through population registries lo-
cated in- and outside the study region. Patients were in-
cluded in this study if they survived longer than 28 days
after AMI had occurred. Those with missing information
on both admission Hb concentration (n = 68) as well as
relevant covariates (n = 176) were excluded. The final study
population consisted of 2011 patients with AMI.
Presence of anemia was defined based on Hb concen-
tration (g/dL) measured at hospital admission and pa-
tients were categorized according to WHO classification
of anemia [6]. Mild anemia was defined as Hb concen-
tration of 11 to < 12 g/dL in women and 11 to < 13 g/dL
in men. Moderate to severe anemia was present when
Hb concentration was below 11 g/dL. Since only thirteen
patients had severe anemia (Hb < 8 g/dL), no further
subdivisions were made.
In order to examine whether an impaired renal function
was present, we used the estimated glomerular filtration rate
(eGFR) and applied the Modification of Diet in Renal Dis-
ease (MDRD) study equation (eGFR (ml/min/1.73 m2) =
186.3 × (serum creatinine− 1.154) x (age− 0.203) × 0.742 (if fe-
male) × 1.212 (if black)) [14] to calculate it. Risk factors such
as history of angina pectoris, prior myocardial infarction,
hypertension, hyperlipidemia, diabetes mellitus, stroke as
well as patients’ smoking habits were covered during the
interview conducted by the study nurses and confirmed by
chart review (except for history of stroke and smoking
habits). Body mass index (BMI; kg/m2), systolic and diastolic
blood pressure as well as heart rate and AMI classification
(ST-segment elevation myocardial infarction (STEMI), non-
ST-segment elevation myocardial infarction (NSTEMI) or
bundle branch block) were derived from chart review only.
Echocardiography, ventriculography and radionuclide ven-
triculography were used to determine whether patients had
a reduced left ventricular ejection fraction (LVEF < 30%).
Furthermore, medications administered at discharge were
documented. The majority of patients received antiplatelet
agents, angiotensin-converting enzyme inhibitors (ACEI) or
angiotensin-receptor-blockers (ARB), beta-blockers and sta-
tins at discharge and therefore, we included these medica-
tions as one covariate (4 evidence-based medications
(EBM); yes/no). In-hospital procedures such as percutan-
eous coronary intervention (PCI) and coronary artery by-
pass graft (CABG) were determined by chart review. Since
in-hospital complications rarely occurred, a single covariate
was generated including the occurrence of cardiac arrest,
pulmonary edema, bradycardia, re-infarction, ventricular
tachycardia, ventricular fibrillation or cardiogenic shock.
Possible differences in survival were tested using Kaplan-
Meyer plots as well as log-rank tests. Hazard ratios (HR) for
all-cause mortality according to anemia status were calcu-
lated using Cox regression models. Three different models
were calculated: 1) an unadjusted model, 2) a model ad-
justed for age and sex, and 3) a model adjusted for age, sex,
previous MI, angina pectoris, hyperlipidemia, diabetes,
stroke, eGFR, heart rate, AMI type, LVEF, discharge medica-
tions, PCI and in-hospital complications. Covariates made it
into the latter model if the corresponding log-rank-test was
statistically significant (p < 0.05) and if they proved to make
a statistically significant contribution to predicting all-cause
mortality in a model together with anemia status. We
graphically tested whether the assumption of proportional
hazards (parallel lines of log (−log (event)) versus log of
event times) was valid for each covariate. Time-dependent
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interaction terms were included if the assumption was
rejected. The covariates age and sex were included into each
model independent of statistical significance. Due to fre-
quently missing data, LVEF was entered into the regression
model as a dummy coded variable (LVEF < 30%; yes/no/
missing). The variance inflation factor (VIF) was used to de-
tect multicollinearity among covariates [15]. Furthermore,
we calculated adjusted Cox regression models for increasing
observation periods ranging from one to 6 years.
As a sensitivity analysis, we calculated a Cox regres-
sion model including all patients who were originally ex-
cluded from our study population due to missing
information on any covariate (n = 176). We adjusted this
model for sex and age. Patients without anemia served
as the reference category for all analyses. P-values of <
0.05 were considered statistically significant. The ana-
lyses were performed using statistical software package
SAS version 9.2 (SAS Institute Inc., Cary, NC).
Results
In total, 283 AMI patients (14.1%) were considered
anemic based on admission Hb concentration. Of those
patients, 183 (64.7%) were mildly anemic, whereas 100
(35.3%) had moderate to severe anemia. Male patients
accounted for 75.6% of the total study population and
the mean age was 60.9 ± 9.6 years. Further patient char-
acteristics are summarized in Table 1.
Patients without anemia differed from the group with
anemia concerning a majority of patient characteristics:
they were significantly younger, had a higher BMI and
were more likely to smoke (see Table 1). In terms of known
comorbidities and other risk factors, the non-anemia group
was overall healthier. They were less likely to have diabetes
and to have suffered from prior myocardial infarction, an-
gina pectoris and stroke. Additionally, they had a signifi-
cantly higher eGFR on admission. Patients with anemia
were less likely to receive antiplatelet agents, ACEIs/ARBs
and statins, but more often received diuretics and insulin at
hospital discharge. Patients with anemia more often had a
LVEF < 30% and information on LVEF was more frequently
missing than in patients without anemia.
During a median follow-up time of 4.2 years (IQR
3.1–5.4), 241 (12.0%) patients with AMI died. Patients
with anemia had a significantly higher long-term mortal-
ity (n = 85, 30.0%) compared to patients without anemia
(n = 156, 9.0%). A higher percentage of patients died in
the group with moderate to severe anemia (n = 37,
37.0%) than in the group with mild anemia (n = 48,
26.2%). Kaplan-Meier plots showing survival curves
stratified by anemia status and the corresponding log-
rank p-value are provided in Fig. 1. Patients who died
during follow-up were significantly older, had a lower
eGFR and were more likely to have an impaired LVEF
compared to those without an event during follow-up
(data not shown). Furthermore, they received four EBM
at discharge significantly less often (data not shown).
Results of the Cox regression analyses are shown in
Table 2.
In the unadjusted model, patients with mild anemia
and patients with moderate to severe anemia had signifi-
cantly increased mortality risks compared to the non-
anemia group by factor of 3.35 and 5.22, respectively.
With increasing adjustment, HRs decreased but still
remained statistically significant. Interaction terms were
each included in a regression model together with
anemia status due to a rejected proportionality assump-
tion for sex, age, BMI, smoking habits, history of angina
pectoris, history of diabetes, AMI type, LVEF, eGFR and
heart rate. None of the interaction terms made a statisti-
cally significant contribution to the models. Despite the
adjustment, patients with moderate to severe anemia
still had a 2 times higher mortality risk (HR 2.05, 95% CI
1.37–3.05) compared to the reference group. In patients
with mild anemia, the risk of dying was increased by
74% in the final model (HR 1.74, 95% CI 1.23–2.45).
Possible multicollinearity among covariates was rejected
since the VIF did not exceed the threshold value of 2.5.
Cox regression models for increasing observation pe-
riods showed decreasing HRs in both groups with
anemia (see Additional file 1: Figure S1). After 1 year,
both anemia groups had a 2.4-times increased risk of
dying. The risk decreased to HRs of 1.7 and 2.1 in pa-
tients with mild anemia and moderate to severe anemia
6 years after AMI, respectively. Estimates drifted apart
starting at 3 years of observation period.
The sensitivity analysis showed increased HRs in pa-
tients with moderate to severe anemia (HR 4.19 vs. 3.94)
and attenuated HRs in patients with mild anemia (HR
2.46 vs. 2.71) compared to the results from our actual
study population (see Additional file 2: Table S1). The
estimates remained statistically significant.
Discussion
In the present analysis, we demonstrated that anemia on
admission both the mild and moderate to severe type was
associated with higher long-term all-cause mortality in pa-
tients hospitalized for AMI. HRs attenuated after multi-
variate adjustment, but a considerable and statistically
significant difference in mortality risk persisted. Similar
risks for patients in both anemia groups were found 1 year
after AMI before they decreased and drifted apart with in-
creasing observation periods.
In patients with coronary artery disease, the prevalence of
anemia on admission varied widely across previous studies
and ranged from 11% [10] to up to 38% [11]. Compared to
most previous studies, the prevalence of anemia in our
population (14.1%) was low [1, 8, 10, 11, 16–21]. Those
studies focused either only on patients with STEMI or
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Table 1 Baseline characteristics and long-term mortality of patients with AMI by anemia status (n = 2011)
Anemiaa (n = 283) Non-anemiad (n = 1728) p Value
Total Mild anemiab
(n = 183)
Moderate to severe anemiac
(n = 100)
Socio-demographic characteristics
Age (years) 64.8 ± 8.5 64.5 ± 8.5 65.4 ± 8.4 60.1 ± 9.6 < 0.0001
Female 70 (24.7) 43 (23.5) 27 (27.0) 440 (25.5) 0.7838
Living alone, (n = 1939) 54 (20.7) 35 (20.2) 19 (21.6) 291 (17.34) 0.4057
Risk factors and medical history
BMI (kg/m2), (n = 1934) 27.2 ± 4.8 27.4 ± 4.8 26.8 ± 4.9 28.0 ± 4.5 0.0272
Smoking status, (n = 1886) < 0.0001
Smoker 55 (22.7) 36 (22.5) 19 (23.2) 661 (40.2)
Ex-smoker 102 (41.2) 70 (43.8) 32 (39.0) 515 (31.3)
Never smoker 85 (35.1) 54 (33.8) 31 (37.8) 468 (28.5)
Prior myocardial infarction 41 (14.5) 24 (13.2) 17 (17.0) 165 (9.6) 0.0228
Angina pectoris 71 (25.1) 51 (27.9) 20 (20.0) 282 (16.3) 0.0004
Hypertension 230 (81.3) 142 (77.6) 88 (88.0) 1367 (79.1) 0.0830
Hyperlipidemia 164 (58.0) 107 (58.5) 57 (57.0) 1118 (64.7) 0.0884
Diabetes 123 (43.5) 68 (37.2) 55 (55.0) 488 (28.2) < 0.0001
Stroke 38 (13.4) 21 (11.5) 17 (17.0) 85 (4.9) < 0.0001
Laboratory markers
Hemoglobin (g/dL) 11.2 ± 1.6 12.1 ± 0.6 9.5 ± 1.3 14.8 ± 1.3 < 0.0001
eGFR (ml/min/1.73m2) 63.9 (43.4–85.5) 65.9 (47.4–83.4) 60.3 (35.9–88.4) 78.3 (64.4–92.3) < 0.0001
eGFR < 60 ml/min/1.73m2 122 (43.1) 73 (39.9) 49 (49.0) 329 (19.0) < 0.0001
Clinical characteristics
Systolic blood pressure (mmHg) 120 ± 17 120 ± 16 121 ± 19 118 ± 15 0.0746
Diastolic blood pressure (mmHg) 68 ± 10 68 ± 10 67 ± 11 69 ± 10 0.1236
Heart rate (bpm) 73 ± 11 73 ± 11 73 ± 10 71 ± 10 0.0004
AMI type < 0.0001
STEMI 63 (22.3) 46 (25.14) 17 (17.0) 616 (35.6)
NSTEMI 194 (68.6) 120 (65.6) 74 (74.0) 1019 (59.0)
Bundle branch block 26 (9.2) 17 (9.3) 9 (9.0) 93 (5.4)
LVEF (n = 1188) 0.0021
LVEF < 30% 4 (2.9) 3 (1.6) 1 (1.0) 38 (2.2)
LVEF ≥30% 132 (46.6) 87 (47.5) 45 (45.0) 1014 (58.7)
Missing 147 (51.9) 93 (50.8) 54 (54.0) 676 (39.1)
Medication at discharge
Antiplatelet agents 263 (92.9) 172 (94.0) 91 (91.0) 1686 (97.6) < 0.0001
ACEIs/ARBs 225 (79.5) 149 (81.4) 76 (76.0) 1493 (86.4) 0.0045
Beta-blocker 271 (95.8) 175 (95.6) 96 (96.0) 1728 (96.1) 0.9595
Statins 239 (84.5) 161 (88.0) 78 (78.0) 1636 (94.7) < 0.0001
4 EBM 178 (62.9) 125 (68.3) 53 (53.0) 1358 (78.6) < 0.0001
Calcium channel blocker 49 (17.3) 33 (18.0) 16 (16.0) 216 (12.5) 0.0758
Diuretics 184(65.0) 115 (62.8) 69 (69.0) 877 (50.8) < 0.0001
Insulin 57 (20.1) 30 (16.4) 27 (27.0) 147 (8.5) < 0.0001
Other antidiabetic agents 51 (18.0) 31 (16.9) 20 (20.0) 225 (13.0) 0.0594
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Table 1 Baseline characteristics and long-term mortality of patients with AMI by anemia status (n = 2011) (Continued)
Anemiaa (n = 283) Non-anemiad (n = 1728) p Value
Total Mild anemiab
(n = 183)
Moderate to severe anemiac
(n = 100)
In-hospital treatment
PCI 139 (49.1) 102 (55.7) 37 (37.0) 1335 (77.3) < 0.0001
CABG 66 (23.3) 39 (21.3) 27 (27.0) 235 (13.6) < 0.0001
Any in-hospital complicatione 51 (18.0) 31 (16.9) 20 (20.0) 229 (13.3) 0.0773
Outcome
All-cause mortality 85 (30.0) 48 (26.2) 37 (37.0) 156 (9.0) < 0.0001
AMI acute myocardial infarction, ACEI angiotensin-converting enzyme inhibitor, ARB angiotensin-receptor blocker, BMI body mass index, CABG coronary artery
bypass graft, EBM evidence-based medications (antiplatelet agents, ACEIs/ARBs, beta-blockers, statins), eGFR estimated glomerular filtration rate, LVEF left ventricular
ejection fraction, PCI percutaneous coronary intervention
Data are presented as n (%), mean ± standard deviation or median (interquartile range (25%-quartile – 75%-quartile))
a Anemia: Hemoglobin (Hb) concentration of < 12 g/dL in women, Hb concentration of < 13 g/dL in men
b Mild anemia: Hb concentration of 11 g/dL to < 12 g/dL in women, Hb concentration of 11 g/dL to < 13 g/dL in men
c Moderate to severe anemia: Hb concentration of < 11 g/dL in men and women
d Non-anemia: Hb concentration of ≥12 g/dL in women, Hb concentration of ≥13 g/dL in men
e Any in-hospital complication includes at least one of the following: cardiac arrest, pulmonary edema, bradycardia, re-infarction, ventricular tachycardia, ventricu-
lar fibrillation, cardiogenic shock
Fig. 1 Kaplan-Meier curve with log-rank test p-value of 6-year survival by anemia status. Hb, Hemoglobin
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included all patients with acute coronary syndrome (ACS),
which might explain the disparities. A higher prevalence of
anemia was found in previous studies in patients with AMI
[1, 5, 11]. This could derive from the fact that we excluded
patients who survived for 28 days or less, which reduced
the prevalence of anemia in our study population.
In line, studies with observation periods of at least 1 year
found significant associations between admission anemia
and long-term mortality [1, 16, 18, 22–24]. Anemia pre-
dicted 1-year survival in ACS patients [18] and 2-year sur-
vival or AMI in men with ACS [22]. In patients with
STEMI, anemia was significantly associated with an in-
creased cardiovascular mortality risk after 21 months [23],
major cardiovascular events (MACE) after 5-years [16]
and all-cause mortality after 6-years of follow-up [24].
Ducrocq et al. examined 3541 patients with AMI and
found a 5-year mortality risk increased by 40% in patients
with anemia (HR 1.4, 95% CI 1.2–1.6) [1]. In comparison,
the mortality risk found in patients with anemia from our
study population was increased by 80%. Among other
known risk factors, Ducrocq et al. adjusted their regres-
sion analysis for in-hospital bleeding and transfusion [1].
Studies have shown that patients with anemia are more
susceptible to experience major bleeding after cardiac
events and revascularization [3, 25], which might also
affect their long-term mortality risk [1, 25]. Apart from
advising to use certain antiplatelet agents with care to
avoid bleeding in patients with anemia after AMI [26],
current clinical practice guidelines do not provide specific
recommendations for the management of anemia in those
patients [27]. In terms of AMI treatment using PCI, a
study showed that radial instead of femoral access might
reduce the risk of bleeding in patients with AMI [28]. Due
to the lower risk of bleeding, the radial access might also
be preferable when performing PCI in patients with
anemia. Furthermore, assuming that patients with anemia
are more likely to receive blood transfusion than patients
without anemia, an increased risk of “transfusion-associ-
ated mortality” [29] might exist. Clinical practice guide-
lines regarding blood transfusion recommend a Hb
threshold of 7–8 g/dL in hospitalized patients [30]. How-
ever, transfusion should be taken into consideration in pa-
tients with acute coronary syndrome and a Hb
concentration of 8–10 g/dL [30]. Data on both in-hospital
bleeding and transfusion were not collected in the frame-
work of the registry and, therefore, the possibility exists
that we overestimated the mortality risk in patients with
anemia. Given the prognostic importance, future studies
should include data on bleeding as well as blood transfu-
sions and a Hb threshold for blood transfusion in patients
with AMI should be determined.
Furthermore, we subdivided patients with anemia and
found increased mortality risks already in patients with
mildly reduced Hb concentration. This could have been
concealed in previous studies only distinguishing between
patients with anemia and those without. Younge et al. ex-
amined patients with ACS (defined as STEMI or NSTEMI)
who were followed up for over 20 years and found signifi-
cantly increased mortality risks in those with moderate (HR
1.13) and severe anemia (HR 1.39), but not in those with
mild anemia [11]. In their study, patients with anemia were
subdivided by tertiles, which deviated from the WHO clas-
sification. The cut-off points, especially those for men with
mild anemia (12.2–13.0 g/dL vs. 11–13 g/dL in our study)
might be responsible for different survival estimates found
in their study [11]. Nonetheless, both our and their results
stress the need to account for severity of anemia in future
studies. Furthermore, our analysis of increasing observation
periods showed that severity of anemia might not be im-
portant in the first 2 years after AMI but might become
more relevant in subsequent years.
Inconsistent with our results, a study in patients with
STEMI treated with primary PCI did not confirm an
association after 3 years of follow-up [19]. Besides it
Table 2 Cox regression models for long-term mortality following AMI by anemia status (n = 2011)
Anemiaa (n = 283) Non-anemiad
(n = 1728)Total Mild anemiab (n = 183) Moderate to severe anemiac (n = 100)
HR [95% CI] p Value HR [95% CI] p Value HR [95% CI] p Value HR [95% CI]
Unadjusted model 3.99 [3.07–5.20] < 0.0001 3.35 [2.45–4.68] <.00001 5.22 [3.64–7.48] < 0.0001 Ref.
Model 1e 3.13 [2.39–4.11] < 0.0001 2.71 [1.95–3.77] < 0.0001 3.94 [3.73–5.68] < 0.0001 Ref.
Model 2f 1.85 [1.37–2.49] < 0.0001 1.74 [1.23–2.45] 0.0017 2.05 [1.37–3.05] 0.0004 Ref.
AMI acute myocardial infarction, CI confidence interval, HR hazard ratio, Ref reference category
a Anemia: Hemoglobin (Hb) concentration of < 12 g/dL in women, Hb concentration of < 13 g/dL in men
b Mild anemia: Hb concentration of 11 g/dL to < 12 g/dL in women, Hb concentration of 11 g/dL to < 13 g/dL in men
c Moderate to severe anemia: Hb concentration of < 11 g/dL in men and women
d Non-anemia: Hb concentration of ≥12 g/dL in women, Hb concentration of ≥13 g/dL in men
e Model 1: Adjusted for age and sex
f Model 2: Model 1 + previous myocardial infarction, angina pectoris, hyperlipidemia, diabetes, stroke, eGFR, heart rate, AMI type (STEMI, NSTEMI, Bundle branch
block), left-ventricular ejection fraction (LVEF) < 30%, medications at discharge (evidence-based medications (antiplatelet agents, angiotensin-converting-enzyme
inhibitor (ACEI), angiotensin-receptor blocker (ARB), beta-blocker, statins), calcium channel blockers, diuretics), percutaneous coronary intervention (PCI) and any
in-hospital complication
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being a single center study, differences in study population
could explain the inconsistency with our results. Further-
more, the authors argue that not anemia itself might nega-
tively impact long-term survival, but rather other
comorbidities could explain the worse prognosis [19]. In
our study and most previous studies [1, 10, 11, 23], patients
with anemia were more likely to be older, were affected by
more comorbidities, had an impaired eGFR as well as a
lower LVEF. Even though important comorbidities were in-
cluded in our analysis, data on other measures of overall
health status were not available. Additionally, patients with
anemia differed from those without anemia regarding in-
hospital treatment. They were less often treated with PCI,
but more frequently with CABG, which might be an indica-
tor of more advanced coronary artery disease. In line, previ-
ous studies demonstrated that anemic patients were less
often treated with PCI [18, 21] and experienced worse out-
comes after PCI, e.g. increased risks for stent thrombosis,
long-term mortality, MACE and bleeding [3, 4, 23, 31]. Fur-
thermore, patients with anemia were less likely to receive 4
EBM at hospital discharge, which is considered the stand-
ard of care in patients after AMI and has been shown to
significantly reduce long-term mortality [32]. Out of the 4
EBM, both patients with mild and moderate to severe
anemia were less likely to receive antiplatelet agents,
ACEIs/ARBs and statins compared to patients without
anemia. In line, a study in STEMI patients showed that
those with anemia were less frequently treated according to
guidelines in terms of pharmacological treatment compared
to those without anemia [20]. However, less often receiving
4 EBM could also be a consequence of other pre-existing
diseases apart from anemia such as impaired renal function
[33].
Multiple factors might influence long-term mortality
after AMI in patients with anemia. When anemia is
present, the amount of oxygen delivered to the heart
during AMI is further decreased, myocardial tissue oxy-
genation is likely to be insufficient and cardiac output is
increased [31, 34]. Possibly entailing an impaired recov-
ery after AMI [16], anemia might affect mortality, but
cannot solely explain the significantly worse long-term
outcomes in patients with AMI. Even though both mild
and moderate to severe anemia did predict an increased
risk for long-term mortality independent of a number of
confounders in our study population, treatment strat-
egies that aim at increasing Hb concentration in patients
with AMI and anemia might not significantly benefit
long-term survival. In line, a recent randomized con-
trolled trial demonstrated that administering erythropoi-
etin after PCI, a hypoxia-induced hormone that also
regulates Hb concentration, did not have beneficial ef-
fects on long-term outcomes [35].
Our study is characterized by several strengths. Data was
collected in the framework of a population-based registry
and patients with AMI were consecutively enrolled. Im-
portant risk factors such as comorbidities, in-hospital treat-
ment and complications, relevant laboratory values as well
as medications received at hospital discharge were included
in our analysis. A longer follow-up than most previous
studies and the analysis of increasing observation periods
add valuable information to existing research.
This study has limitations. First, even though several
risk factors potentially affecting survival after AMI were
included, data on cancer, gastro-intestinal or other
chronic diseases was not collected. Second, we had no
information on the etiology of anemia and how it was
treated (e.g. using iron therapy). Knowing the cause of
abnormal Hb concentrations would considerably con-
tribute to the understanding of the association between
anemia and long-term mortality. Third, any other events
occurring after hospital-discharge apart from all-cause
mortality and possibly affecting survival could not be
monitored. Fourth, a reduced LVEF is a marker for heart
failure and data on LVEF was not available in all patients
in our study population. Since we included those pa-
tients with missing values for left-ventricular ejection
fraction we cannot rule out potential bias. Finally, due to
the methodological limitations of an observational study,
a causal relationship between admission anemia and
long-term mortality cannot be established with absolute
certainty and the possibility of reverse causation exists.
Conclusion
Both mild and moderate to severe anemia were associated
with significantly increased long-term, all-cause mortality
risks in our study population and low admission Hb con-
centration needs to be considered as a risk factor in pa-
tients with AMI. However, even though our results
confirm what most other studies have found in patients
with AMI before, it remains unclear if anemia alone can
predict long-term mortality after AMI or if it is merely a
proxy for worse overall health. Future studies need to take
severity of anemia, bleeding events and blood transfusion
as well as overall health status into account.
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Additional file 1: Figure S1. Hazard ratios for long-term mortality in pa-
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< 12 g/dL in women, Hb concentration of 11 g/dL to < 13 g/dL in men. Mod-
erate to severe anemia: Moderate to severe anemia: Hb concentration of <
11 g/dL in women and men. 95% Confidence intervals (CI) are represented by
vertical lines above and below the HR estimates; 95% CI for mild anemia:
dashed line; 95% CI for moderate to severe anemia: continuous line. AMI, Acute
myocardial infarction; CI, Confidence interval; Hb, Hemoglobin; HR, Hazard ratio.
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Additional file 2: Table S1. Results of the sensitivity analysis (n = 2187).
(DOCX 16 kb)
Colombo et al. BMC Cardiovascular Disorders  (2018) 18:50 Page 7 of 9
Abbreviations
ACEI: Angiotensin-converting enzyme inhibitor; ACS: Acute coronary
disease; AMI: Acute myocardial infarction; ARB: Angiotensin-receptor
blockers; BMI: Body mass index; CABG: Coronary artery bypass graft;
EBM: Evidence-based medication; eGFR: Estimated glomerular filtration
rate; Hb: Hemoglobin; HR: Hazard ratio; IQR: Interquartile range;
KORA: Cooperative Health Research in the Region of Augsburg;
LVEF: Left ventricular ejection fraction; MACE: Major cardiovascular
event; MDRD: Modification of Diet in Renal Disease; MI: Myocardial
infarction; MONICA: Monitoring Trends and Determinants in
Cardiovascular disease; NSTEMI: Non-ST-segment elevation myocardial
infarction; PCI: Percutaneous coronary intervention; SD: Standard
deviation; SPC: Serum potassium concentration; STEMI: ST-elevation
myocardial infarction; VIF: Variance inflation factor; WHO: World Health
Organization
Acknowledgements
We thank all members of the Helmholtz Zentrum München, Institute
of Epidemiology and the field staff in Augsburg who were involved in
the planning and conduct of the study. We wish to thank the local
health departments, the office-based physicians and the clinicians of
the hospitals within the study area for their support. Finally, we
express our appreciation to all study participants.
Funding
The KORA research platform and the MONICA Augsburg studies were
initiated and financed by the Helmholtz Zentrum München, German
Research Center for Environmental Health, which is funded by the
German Federal Ministry of Education, Science, Research and
Technology and by the State of Bavaria. Since the year 2000, the
collection of MI data has been co-financed by the German Federal
Ministry of Health to provide population-based MI morbidity data for
the official German Health Report (see www.gbe-bund.de). Steering
partners of the MONICA/KORA Infarction Registry, Augsburg, include
the KORA research platform, Helmholtz Zentrum München and the
Department of Internal Medicine I, Cardiology, Central Hospital of
Augsburg.
Availability of data and materials
The data that support the findings of this study are available from
Helmholtz Zentrum München but restrictions apply to the availability
of data, which were used under license for the current study, and are
not publicly available. Due to restrictions from Helmholtz Zentrum
München, data are available upon request for any researcher based on
a standard agreement on data provision within the KORA Research
Platform.
Authors’ contributions
MGC, IK and CM conceived the study. MGC performed the statistical analyses and
drafted the manuscript. CM, UA, MH, BK, CT and AP contributed to the
interpretation of data. CM, MH, BK and CT contributed to data acquisition. IK, UA,
MH, CT, BK, AP and CM read, critically revised and approved the final manuscript.
Ethics approval and consent to participate
Data collection and follow-up questionnaires have been approved by the ethics
committee of the Bavarian Medical Association (Bayerische Landesärztekammer)
and have been performed in accordance with the Declaration of Helsinki. All
study participants gave written informed consent.
Consent for publication
Not applicable.
Competing interests
The authors declare that they have no competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1MONICA/KORA Myocardial Infarction Registry, Central Hospital of Augsburg,
Augsburg, Germany. 2Institute of Epidemiology, Helmholtz Zentrum
München, German Research Center for Environmental Health (GmbH),
Neuherberg, Germany. 3Chair of Epidemiology,
Ludwig-Maximilians-Universität München, UNIKA-T, Augsburg, Germany.
4Department of Internal Medicine I – Cardiology, Central Hospital of
Augsburg, Augsburg, Germany. 5Department of Internal Medicine/
Cardiology, Hospital of Nördlingen, Nördlingen, Germany.
Received: 30 November 2017 Accepted: 26 February 2018
References
1. Ducrocq G, Puymirat E, Steg PG, Henry P, Martelet M, Karam C, Schiele F,
Simon T, Danchin N. Blood transfusion, bleeding, anemia, and survival in
patients with acute myocardial infarction: FAST-MI registry. Am Heart J.
2015;170(4):726–34. e722
2. Leibundgut G, Gick M, Morel O, Ferenc M, Werner KD, Comberg T, Kienzle
RP, Buettner HJ, Neumann FJ. Discordant cardiac biomarker levels
independently predict outcome in ST-segment elevation myocardial
infarction. Clin Res Cardiol. 2016;105(5):432–40.
3. Wang X, Qiu M, Qi J, Li J, Wang H, Li Y, Han Y. Impact of anemia on long-
term ischemic events and bleeding events in patients undergoing
percutaneous coronary intervention: a system review and meta-analysis. J
Thorac Dis. 2015;7(11):2041–52.
4. Nikolsky E, Mehran R, Aymong ED, Mintz GS, Lansky AJ, Lasic Z, Negoita M, Fahy
M, Pocock SJ, Na Y, et al. Impact of anemia on outcomes of patients undergoing
percutaneous coronary interventions. Am J Cardiol. 2004;94(8):1023–7.
5. Aronson D, Suleiman M, Agmon Y, Suleiman A, Blich M, Kapeliovich M,
Beyar R, Markiewicz W, Hammerman H. Changes in haemoglobin levels
during hospital course and long-term outcome after acute myocardial
infarction. Eur Heart J. 2007;28(11):1289–96.
6. Haemoglobin concentrations for the diagnosis of anaemia and assessment
of severity. Vitamin and Mineral Nutrition Information System [http://www.
who.int/vmnis/indicators/haemoglobin.pdf].
7. Martinsson A, Andersson C, Andell P, Koul S, Engstrom G, Smith JG. Anemia
in the general population: prevalence, clinical correlates and prognostic
impact. Eur J Epidemiol. 2014;29(7):489–98.
8. Ang DS, Kao MP, Noman A, Lang CC, Struthers AD. The prognostic
significance of early and late anaemia in acute coronary syndrome. QJM.
2012;105(5):445–54.
9. Jonsson A, Hallberg AC, Edner M, Lund LH, Dahlstrom U. A
comprehensive assessment of the association between anemia,
clinical covariates and outcomes in a population-wide heart failure
registry. Int J Cardiol. 2016;211:124–31.
10. Bolinska S, Sobkowicz B, Zaniewska J, Chlebinska I, Bolinski J, Milewski R,
Tycinska A, Musial W. The significance of anaemia in patients with acute ST-
elevation myocardial infarction undergoing primary percutaneous coronary
intervention. Kardiol Pol. 2011;69(1):33–9.
11. Younge JO, Nauta ST, Akkerhuis KM, Deckers JW, van Domburg RT. Effect of
anemia on short- and long-term outcome in patients hospitalized for acute
coronary syndromes. Am J Cardiol. 2012;109(4):506–10.
12. Meisinger C, Hormann A, Heier M, Kuch B, Lowel H. Admission blood
glucose and adverse outcomes in non-diabetic patients with myocardial
infarction in the reperfusion era. Int J Cardiol. 2006;113(2):229–35.
13. Kuch B, Heier M, von Scheidt W, Kling B, Hoermann A, Meisinger C. 20-year
trends in clinical characteristics, therapy and short-term prognosis in acute
myocardial infarction according to presenting electrocardiogram: the
MONICA/KORA AMI registry (1985-2004). J Intern Med. 2008;264(3):254–64.
14. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate
method to estimate glomerular filtration rate from serum creatinine: a new
prediction equation. Modification of diet in renal disease study group. Ann
Intern Med. 1999;130(6):461–70.
15. When can you safely ignore multicollinearity? [http://statisticalhorizons.com/
multicollinearity].
16. Uchida Y, Ichimiya S, Ishii H, Kanashiro M, Watanabe J, Hayano S, Suzuki S,
Takeshita K, Sakai S, Amano T, et al. Impact of admission anemia on
coronary microcirculation and clinical outcomes in patients with ST-
segment elevation myocardial infarction undergoing primary percutaneous
coronary intervention. Int Heart J. 2015;56(4):381–8.
Colombo et al. BMC Cardiovascular Disorders  (2018) 18:50 Page 8 of 9
17. Barbarova I, Klempfner R, Rapoport A, Wasserstrum Y, Goren I, Kats A, Segal
G. Avoidance of blood transfusion to patients suffering from myocardial
injury and severe anemia is associated with increased long-term mortality: a
retrospective cohort analysis. Medicine (Baltimore). 2015;94(38):e1635.
18. Kunadian V, Mehran R, Lincoff AM, Feit F, Manoukian SV, Hamon M, Cox DA,
Dangas GD, Stone GW. Effect of anemia on frequency of short- and long-term
clinical events in acute coronary syndromes (from the acute catheterization and
urgent intervention triage strategy trial). Am J Cardiol. 2014;114(12):1823–9.
19. Rathod KS, Jones DA, Rathod VS, Bromage D, Guttmann O, Gallagher SM,
Mohiddin S, Rothman MT, Knight C, Jain AK, et al. Prognostic impact of
anaemia on patients with ST-elevation myocardial infarction treated by
primary PCI. Coron Artery Dis. 2014;25(1):52–9.
20. Riley RF, Newby LK, Don CW, Alexander KP, Peterson ED, Peng SA, Gandhi
SK, Kutcher MA, Amsterdam EA, Herrington DM. Guidelines-based treatment
of anaemic STEMI patients: practice patterns and effects on in-hospital
mortality: a retrospective analysis from the NCDR. Eur Heart J Acute
Cardiovasc Care. 2013;2(1):35–43.
21. Sulaiman K, Prashanth P, Al-Zakwani I, Al-Mahmeed W, Al-Motarreb A, Al
Suwaidi J, Amin H, Asaad N, Hersi A, Al Faleh H, et al. Impact of anemia on
in-hospital, one-month and one-year mortality in patients with acute
coronary syndrome from the Middle East. Clin Med Res. 2012;10(2):65–71.
22. Cavusoglu E, Chopra V, Gupta A, Clark LT, Eng C, Marmur JD. Usefulness of
anemia in men as an independent predictor of two-year cardiovascular
outcome in patients presenting with acute coronary syndrome. Am J
Cardiol. 2006;98(5):580–4.
23. Ayhan E, Aycicek F, Uyarel H, Ergelen M, Cicek G, Gul M, Osmonov D,
Yildirim E, Bozbay M, Ugur M, et al. Patients with anemia on admission
who have undergone primary angioplasty for ST elevation myocardial
infarction: in-hospital and long-term clinical outcomes. Coron Artery Dis.
2011;22(6):375–9.
24. Tomaszuk-Kazberuk A, Bolinska S, Mlodawska E, Lopatowska P, Sobkowicz B,
Musial W. Does admission anaemia still predict mortality six years after
myocardial infarction? Kardiol Pol. 2014;72(6):488–93.
25. Tsujita K, Nikolsky E, Lansky AJ, Dangas G, Fahy M, Brodie BR, Dudek D,
Mockel M, Ochala A, Mehran R, et al. Impact of anemia on clinical outcomes
of patients with ST-segment elevation myocardial infarction in relation to
gender and adjunctive antithrombotic therapy (from the HORIZONS-AMI
trial). Am J Cardiol. 2010;105(10):1385–94.
26. Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H,
Caforio ALP, Crea F, Goudevenos JA, Halvorsen S, et al. 2017 ESC guidelines
for the management of acute myocardial infarction in patients presenting
with ST-segment elevation. Rev Esp Cardiol (Engl Ed). 2017;70(12):1082.
27. Kwok CS, Tiong D, Pradhan A, Andreou AY, Nolan J, Bertrand OF, Curzen N,
Urban P, Myint PK, Zaman AG, et al. Meta-analysis of the prognostic impact
of anemia in patients undergoing percutaneous coronary intervention. Am
J Cardiol. 2016;118(4):610–20.
28. Bagai J, Little B, Banerjee S. Association between arterial access site and
anticoagulation strategy on major bleeding and mortality: a historical cohort
analysis in the veteran population. Cardiovasc Revasc Med. 2018;19(1 Pt B):95–101.
29. Salisbury AC, Reid KJ, Marso SP, Amin AP, Alexander KP, Wang TY, Spertus
JA, Kosiborod M. Blood transfusion during acute myocardial infarction:
association with mortality and variability across hospitals. J Am Coll Cardiol.
2014;64(8):811–9.
30. Carson JL, Guyatt G, Heddle NM, Grossman BJ, Cohn CS, Fung MK,
Gernsheimer T, Holcomb JB, Kaplan LJ, Katz LM, et al. Clinical practice
guidelines from the AABB: red blood cell transfusion thresholds and
storage. JAMA. 2016;316(19):2025–35.
31. Pilgrim T, Vetterli F, Kalesan B, Stefanini GG, Raber L, Stortecky S,
Gloekler S, Binder RK, Wenaweser P, Moschovitis A, et al. The impact of
anemia on long-term clinical outcome in patients undergoing
revascularization with the unrestricted use of drug-eluting stents. Circ
Cardiovasc Interv. 2012;5(2):202–10.
32. Amann U, Kirchberger I, Heier M, Goluke H, von Scheidt W, Kuch B, Peters A,
Meisinger C. Long-term survival in patients with different combinations of
evidence-based medications after incident acute myocardial infarction:
results from the MONICA/KORA myocardial infarction registry. Clin Res
Cardiol. 2014;103(8):655–64.
33. Khedri M, Szummer K, Carrero JJ, Jernberg T, Evans M, Jacobson SH, Spaak J.
Systematic underutilisation of secondary preventive drugs in patients with
acute coronary syndrome and reduced renal function. Eur J Prev Cardiol.
2017;24(7):724–734.
34. Willis P, Voeltz MD. Anemia, hemorrhage, and transfusion in percutaneous
coronary intervention, acute coronary syndromes, and ST-segment elevation
myocardial infarction. Am J Cardiol. 2009;104(5 Suppl):34C–8C.
35. Steppich B, Groha P, Ibrahim T, Schunkert H, Laugwitz KL, Hadamitzky M,
Kastrati A, Ott I, Regeneration of Vital Myocardium in STSEMIbESI. Effect of
erythropoietin in patients with acute myocardial infarction: five-year results
of the REVIVAL-3 trial. BMC Cardiovasc Disord. 2017;17(1):38.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Colombo et al. BMC Cardiovascular Disorders  (2018) 18:50 Page 9 of 9
